The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

Trends in Molecular Medicine

Volumn 14, Issue 3, 2008, Pages 109-119

  Naugler, Willscott E ^a   Karin, Michael ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Departments of Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADAPTIVE IMMUNITY; AGING; BIOLOGICAL ACTIVITY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENTERITIS; HUMAN; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN RESISTANCE; MEDIATOR; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; OBESITY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

AGING; ANIMALS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INSULIN RESISTANCE; INTERLEUKIN-6; MICE; NEOPLASMS; OBESITY; RHEUMATIC FEVER; SIGNAL TRANSDUCTION;

OVIS ARIES;

EID: 40649109728     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.12.007     Document Type: Review

References (105)

1. Hirano T., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324 (1986) 73-76
2. Dendorfer U., et al. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol. Cell. Biol. 14 (1994) 4443-4454
3. Trautwein C., et al. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Nature 364 (1993) 544-547
4. Vanden Berghe W., et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem. Pharmacol. 60 (2000) 1185-1195
5. Naugler W.E., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124
6. Karin M., et al. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124 (2006) 823-835
7. Heinrich P.C., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003) 1-20
8. Taub R. Liver regeneration 4: transcriptional control of liver regeneration. FASEB J. 10 (1996) 413-427
9. Kubo M., et al. Suppressors of cytokine signaling and immunity. Nat. Immunol. 4 (2003) 1169-1176
10. Li W., et al. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J. Biol. Chem. 277 (2002) 28411-28417
11. Rose-John S., et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80 (2006) 227-236
12. Mitsuyama K., et al. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 17 (2006) 451-461
13. Cronstein B.N. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 65 Suppl. 1 (2007) S11-S15
14. Soresi M., et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol. 12 (2006) 2563-2568
15. Wolvekamp M.C., and Marquet R.L. Interleukin-6: historical background, genetics and biological significance. Immunol. Lett. 24 (1990) 1-9
16. Muraguchi A., et al. T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J. Immunol. 127 (1981) 412-416
17. Hirano T., et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 5490-5494
18. Kopf M., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368 (1994) 339-342
19. Xing Z., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101 (1998) 311-320
20. Hurst S.M., et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14 (2001) 705-714
21. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005) 1123-1132
22. Park H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6 (2005) 1133-1141
23. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
24. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182 (2001) 18-32
25. Bettelli E., et al. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8 (2007) 345-350
26. Liang S.C., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203 (2006) 2271-2279
27. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116 (2006) 1218-1222
28. Nakae S., et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171 (2003) 6173-6177
29. Komiyama Y., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 566-573
30. Alonzi T., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187 (1998) 461-468
31. Okuda Y., et al. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 101 (1999) 188-196
32. Mangan P.R., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
33. + T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
34. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340 (1999) 448-454
35. Nasraway S.A. The problems and challenges of immunotherapy in sepsis. Chest 123 (2003) 451S-459S
36. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 115 (2005) 1111-1119
37. Fearnley G.R., et al. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet 2 (1959) 1067
38. Ogston D., and McAndrew G.M. Fibrinolysis in obesity. Lancet 2 (1964) 1205-1207
39. Dandona P., et al. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25 (2004) 4-7
40. Shoelson S.E., et al. Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007) 2169-2180
41. Kern P.A., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E745-E751
42. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11 (2005) 183-190
43. Arkan M.C., et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11 (2005) 191-198
44. Solinas G., et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16454-16459
45. Klover P.J., et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52 (2003) 2784-2789
46. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8 (2002) 75-79
47. Nielsen O.H., et al. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 38 (2003) 180-185
48. Fujino S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
49. Hyams J.S., et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 104 (1993) 1285-1292
50. Umehara Y., et al. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology 53 (2006) 879-882
51. Van Kemseke C., et al. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int. J. Colorectal Dis. 15 (2000) 206-210
52. Van Limbergen J., et al. Genetics of the innate immune response in inflammatory bowel disease. Inflamm. Bowel Dis. 13 (2007) 338-355
53. Yamamoto M., et al. IL-6 Is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164 (2000) 4878-4882
54. Greten F.R., et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
55. McLoughlin R.M., et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9589-9594
56. Atreya R., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6 (2000) 583-588
57. Ito H., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004) 989-996
58. Madhok R., et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 52 (1993) 232-234
59. Sack U., et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int. 13 (1993) 45-51
60. Sasai M., et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42 (1999) 1635-1643
61. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
62. van der Heijden I.M., et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum. 43 (2000) 593-598
63. Han Z., et al. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28 (1998) 197-208
64. Tarner I.H., et al. Emerging targets of biologic therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 3 (2007) 336-345
65. Chabaud M., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42 (1999) 963-970
66. McInnes I.B., and Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7 (2007) 429-442
67. Nishimoto N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50 (2004) 1761-1769
68. Maini R.N., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54 (2006) 2817-2829
69. Sarkar D., and Fisher P.B. Molecular mechanisms of aging-associated inflammation. Cancer Lett. 236 (2006) 13-23
70. Maggio M., et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci. 61 (2006) 575-584
71. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
72. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
73. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006) 431-436
74. Kuper H., et al. Infections as a major preventable cause of human cancer. J. Intern. Med. 248 (2000) 171-183
75. Karin M., and Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
76. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
77. Li Q., et al. Inflammation-associated cancer: NF-κB is the lynchpin. Trends Immunol. 26 (2005) 318-325
78. Haura E.B., et al. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2 (2005) 315-324
79. Klein B., et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73 (1989) 517-526
80. Lattanzio G., et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am. J. Pathol. 151 (1997) 689-696
81. Annunziata C.M., et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12 (2007) 115-130
82. Keats J.J., et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12 (2007) 131-144
83. Aggarwal B.B., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091 (2006) 151-169
84. Becker C., et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21 (2004) 491-501
85. Chung Y.C., and Chang Y.F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 83 (2003) 222-226
86. Rakoff-Nahoum S., and Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317 (2007) 124-127
87. Khoruts A., et al. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13 (1991) 267-276
88. Kakumu S., et al. Serum interleukin 6 levels in patients with chronic hepatitis B. Am. J. Gastroenterol. 86 (1991) 1804-1808
89. Malaguarnera M., et al. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int. J. Clin. Pharmacol. Ther. 35 (1997) 385-388
90. Malaguarnera M., et al. Role of interleukin 6 in hepatocellular cancer. Bull. Cancer 83 (1996) 379-384
91. Mauad T.H., et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsupporative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145 (1994) 1237-1245
92. Pikarsky E., et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
93. Maeda S., et al. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
94. Emilie D., et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 84 (1994) 2472-2479
95. Haddad E., et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter Phase 1-2 clinical trial. Blood 97 (2001) 1590-1597
96. Nishimoto N., et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95 (2000) 56-61
97. Nishimoto N., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 (2005) 2627-2632
98. Bataille R., et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86 (1995) 685-691
99. Moreau P., et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol. 109 (2000) 661-664
100. Blay J.Y., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 72 (1997) 424-430
101. Braiteh, F.S. et al. (2006) Phase I study of the safety and efficacy of atiprimod, a novel azaspirine, for patients with advanced cancer [abstract]. ASCO Annual Meeting Proceedings (2006 June 2-6, Atlanta), J. Clin. Oncol. 24 (Suppl. 18S), 13050
102. Kurzrock, R. et al. (2006) Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monocloal antibody (mAb) in subjects with selected hematologic malignancies [abstract]. ASCO Annual Meeting Proceedings (2006 June 2-6, Atlanta), J. Clin. Oncol. 24 (Suppl. 18S), 2513
103. Yokota S., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52 (2005) 818-825
104. Nishimoto N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66 (2007) 1162-1167
105. Iwamoto M., et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 46 (2002) 3388-3389